Hyperparathyroidism primary prevention: Difference between revisions

	Hyperparathyroidism Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Hyperparathyroidism from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
X Ray
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Hyperparathyroidism primary prevention On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Hyperparathyroidism primary prevention All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Hyperparathyroidism primary prevention
CDC on Hyperparathyroidism primary prevention
Hyperparathyroidism primary prevention in the news
Blogs on Hyperparathyroidism primary prevention
Directions to Hospitals Treating Hyperparathyroidism
Risk calculators and risk factors for Hyperparathyroidism primary prevention

Revision as of 16:50, 6 September 2017

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:

Effective measures for the primary prevention of secondary hyperparathyroidism in chronic kidney disease include aggressive management of hyperphosphatemia in early stages of chronic kidney disease and prevention and treatment of vitamin D deficiency in stage 3 & 4 chronic kidney disease. There are no established measures for the primary prevention of primary hyperparathyroidism.

Effective measures for the primary prevention of secondary hyperparathyroidism in chronic kidney disease include:^[1]
- Aggressive management of hyperphosphatemia in early stages of chronic kidney disease
- Prevention and treatment of vitamin D deficiency in stage 3 & 4 chronic kidney disease

There are no established measures for the primary prevention of primary hyperparathyroidism.

@@ Line 5: / Line 5: @@
 ==Overview==
-*There are no established measures for the primary prevention of [disease name].
+*Effective measures for the primary prevention of secondary hyperparathyroidism in chronic kidney disease include aggressive management of hyperphosphatemia in early stages of chronic kidney disease and prevention and treatment of vitamin D deficiency in stage 3 & 4 chronic kidney disease. There are no established measures for the primary prevention of primary hyperparathyroidism.
-*There are no available vaccines against [disease name].
-OR
-*Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].
-*[Vaccine name] vaccine is recommended for [patient population] to prevent [disease name]. Other primary prevention strategies include [strategy 1], [strategy 2], and [strategy 3].
 ==Primary Prevention==